Leerink Partners analyst Jonathan Chang maintained a Hold rating on Adaptimmune Therapeutics on August 13 and set a price target of $0.09.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jonathan Chang has given his Hold rating due to a combination of factors surrounding Adaptimmune Therapeutics’ current situation. The company’s recent financial results showed a significant increase in revenue from Tecelra, surpassing expectations, which is a positive indicator. However, the ongoing restructuring efforts following the agreement to sell key assets to US WorldMeds highlight uncertainties regarding the company’s future direction and the development of its remaining preclinical programs.
Moreover, while there are upcoming milestones such as the potential commercial launch of lete-cel by US WorldMeds, these events are still in the early stages and lack immediate clarity. The limited visibility on the next steps for Adaptimmune’s pipeline and the early-stage nature of its remaining programs contribute to the cautious stance. Consequently, Chang maintains a Hold rating, reflecting a balanced view of the company’s current prospects and challenges.
Chang covers the Healthcare sector, focusing on stocks such as Kura Oncology, Zai Lab, and Replimune Group. According to TipRanks, Chang has an average return of -10.2% and a 32.55% success rate on recommended stocks.
In another report released on August 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $0.00 price target.